市場調查報告書
商品編碼
986565

末梢神經病變治療的全球市場預測(2020年∼2026年)

Global Peripheral Neuropathy Treatment Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球末梢神經病變治療市場估計將以4.3%的複合年增長率增長。癌症患病率上升是市場增長的主要驅動力之一。根據世界衛生組織(WHO)的數據,2018年全球癌症的發生率為1810萬新。2018年,過去五年中診斷出的4380萬人患有癌症。癌症發病率的增加導致對破壞體內快速生長的細胞的化學療法的需求增加。但是,某些化學治療劑可引起周圍神經病,導致周圍麻醉藥,包括鎮痛藥,抗抑鬱藥或抗驚厥藥以及利多卡因,常用於疼痛治療,因此對神經病治療的需求不斷增長。此外,如果疼痛非常嚴重,可以使用阿片類藥物。

本報告提供全球末梢神經病變治療市場相關調查分析,提供市場概要,市場決策要素,市場區隔,競爭情形,各地區分析,主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 法律規章

第3章 競爭情形

  • 企業佔有率分析
  • 主要策略分析
  • 主要企業分析
    • Pfizer, Inc.
    • Grunenthal GmbH
    • Novartis International AG
    • Eli Lilly and Co.
    • 第一三共

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 各類型市場
    • 抗憂鬱症藥
    • 止痛藥
    • 抗痙攣藥
    • 其他
  • 各應用領域市場
    • 糖尿病
    • 化療誘發性
    • 其他

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Achelios Therapeutics, Inc.
  • Acorda Therapeutics, Inc.
  • Alembic Pharmaceuticals, Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex, Inc.
  • Assertio Therapeutics, Inc.
  • Bristol Myers Squibb Co.
  • Cipla, Ltd.
  • 第一三共
  • Eli Lilly and Co.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals, Ltd.
  • Grunenthal GmbH
  • Innovus Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin, Ltd.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries, Ltd.
目錄
Product Code: OMR2023006

Global Peripheral Neuropathy Treatment Market Size, Share & Trends Analysis Report, By Type (Antidepressants, Pain Relievers, Antiseizure, and Others), By Application (Diabetes, Chemotherapy-Induced, and Others) and Forecast, 2020-2026

The global peripheral neuropathy treatment market is estimated to grow at a CAGR of 4.3% during the forecast period. The increasing prevalence of cancer is one of the major factors accelerating market growth. As per the World Health Organization (WHO), in 2018, 18.1 million new cancer incidences were reported globally. Globally, in 2018, 43.8 million persons were suffering from cancer who were diagnosed within the last 5 years. Rising cancer incidence has resulted in an increasing demand for chemotherapy to destroy rapidly growing cells in the body. However, some chemotherapy drugs may cause peripheral neuropathy, which is resulting in the demand for peripheral neuropathy treatment in which analgesics, antidepressants, or anticonvulsants, as well as topical numbing agents including lidocaine, are often used for the management of pain. Additionally, opioids may be used in cases that involve extreme pain.

The global peripheral neuropathy treatment market is segmented based on type and application. Based on type, the market is classified into antidepressants, pain relievers, antiseizure, and others. Based on the application, the market is classified into diabetes, chemotherapy-induced, and others. Diabetes is the most common form of neuropathic disorders, which is supporting the adoption of peripheral neuropathy treatment to manage diabetic peripheral neuropathy. It is a severe diabetic complication that may affect nearly 50% of people suffering from diabetes. Therefore, increasing diabetes prevalence is one of the major causes leading to increasing demand for peripheral neuropathy treatment.

Geographically, Asia-Pacific is estimated to grow at the fastest CAGR during the forecast period owing to the rising prevalence of diabetes and cancer. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. In India, the number of new cancer incidences was 1.2 million in 2018. This may result in the demand for peripheral neuropathy treatment to treat nerve pain. The main drugs that are used for neuropathic pain include amitriptyline, duloxetine, gabapentin, and pregabalin.

Some prominent players in the market include Pfizer Inc., Grunenthal GmbH, Novartis International AG, Eli Lilly and Co., and Daiichi Sankyo Co. Ltd. Some strategic initiatives that are implemented by the market players include product launches and partnerships and collaborations. For instance, in November 2018, Grunenthal GmbH acquired a pharmaceutical firm based in the US, Averitas Pharma. This will enable Grunenthal to expand its geographical footprint in the US. Averitas Pharma will commercialize Qutenza (8 % capsaicin), the pain patch for Grunenthal in the US. This acquisition will enable Grunenthal to implement its growth strategy and enhancing its business across several geographies and pain-related therapeutic categories.

Research Methodology

The market study of the global peripheral neuropathy treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Peripheral Neuropathy Treatment Market Research and Analysis by Type

2. Global Peripheral Neuropathy Treatment Market Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global peripheral neuropathy treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global peripheral neuropathy treatment market.
  • Insights about market determinants that are stimulating the global peripheral neuropathy treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Pfizer, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Grunenthal GmbH
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Novartis International AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Eli Lilly and Co.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Daiichi Sankyo Co. Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Peripheral Neuropathy Treatment Market by Type
    • 5.1.1. Antidepressants
    • 5.1.2. Pain Relievers
    • 5.1.3. Antiseizure
    • 5.1.4. Others
  • 5.2. Global Peripheral Neuropathy Treatment Market by Application
    • 5.2.1. Diabetes
    • 5.2.2. Chemotherapy-Induced
    • 5.2.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Achelios Therapeutics, Inc.
  • 7.2. Acorda Therapeutics, Inc.
  • 7.3. Alembic Pharmaceuticals, Ltd.
  • 7.4. Amneal Pharmaceuticals LLC
  • 7.5. Apotex, Inc.
  • 7.6. Assertio Therapeutics, Inc.
  • 7.7. Bristol Myers Squibb Co.
  • 7.8. Cipla, Ltd.
  • 7.9. Daiichi Sankyo Company, Ltd.
  • 7.10. Eli Lilly and Co.
  • 7.11. GlaxoSmithKline plc
  • 7.12. Glenmark Pharmaceuticals, Ltd.
  • 7.13. Grunenthal GmbH
  • 7.14. Innovus Pharmaceuticals, Inc.
  • 7.15. Johnson & Johnson Services, Inc.
  • 7.16. Lupin, Ltd.
  • 7.17. Mylan N.V.
  • 7.18. Novartis International AG
  • 7.19. Pfizer, Inc.
  • 7.20. Teva Pharmaceutical Industries, Ltd.

LIST OF TABLES

  • 1. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL ANTIDEPRESSANTS FOR PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL PAIN RELIEVERS FOR PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ANTISEIZURE FOR PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL OTHER PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 7. GLOBAL DIABETIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL PERIPHERAL NEUROPATHY TREATMENT IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 14. EUROPEAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. EUROPEAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 16. EUROPEAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLD PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 3. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)